01—Abstract
Summary
Summary of the 8-K filed May 24, 2024. Cited figures are marked; the original filing is the authoritative source.
On May 22, 2024, Cencora (COR) agreed to repurchase 1,859,390 shares of its common stock from Walgreens Boots Alliance Holdings LLC at $215.1244a per share, for approximately $400 million in a private transaction.
The deal closed May 24, 2024, and the shares will be held in treasury. It was executed under the company's existing share repurchase programs, and the filing describes it as an opportunistic capital return rather than a change in strategy. After the repurchase, Walgreens owns 24,418,171 shares, about 12%b of the 196,928,527 shares outstanding.
Walgreens was a major holder seeking to monetize its stake, so this transaction reduces the overhang from a large block seller and supports the share price. The company also raised its fiscal 2024 adjusted diluted EPS guidance to $13.35c–$13.55 from $13.30–$13.50, citing a lower weighted average diluted share count, partly offset by higher net interest expense from lower investment balances after using cash for buybacks.
For investors, the key points are the scale of the capital deployment (about $550 milliond of repurchases in May 2024 alone), the modest EPS guidance increase driven mainly by share count reduction, and the trade-off of lower cash balances and higher net interest expense. The filing does not disclose the impact on leverage or remaining authorization capacity, which investors may want to review in upcoming periodic reports.
02—Key points
Key Highlights
- Cencora repurchased 1,859,390 shares directly from Walgreens Boots Alliance at $215.1244 per share, for approximately $400 million, closing May 24, 2024.
- Repurchased shares will be held in treasury and were made under existing share repurchase programs.
- Walgreens retains 24,418,171 shares, roughly 12% of Cencora's outstanding common stock after the transaction.
- Fiscal 2024 adjusted diluted EPS guidance was raised to $13.35–$13.55 from $13.30–$13.50.
- The EPS increase reflects a lower weighted average diluted share count, partly offset by higher net interest expense from reduced investment balances.
- Cencora completed approximately $550 million of share repurchases in May 2024, which the company describes as an opportunistic approach to capital return.
- The Share Repurchase Agreement is filed as Exhibit 10.1 and the press release as Exhibit 99.1, with Item 7.01 furnished rather than filed.
03—Questions
Frequently Asked Questions
Why did Cencora repurchase shares from Walgreens?
The filing describes the repurchase as an opportunistic use of capital under the company's existing buyback programs. Buying a large block directly from a major holder allowed Cencora to retire shares in a single private transaction at a price of $215.1244 per share.
How does the repurchase affect Cencora's EPS guidance?
Cencora raised its fiscal 2024 adjusted diluted EPS guidance by $0.05 at both ends of the range, to $13.35–$13.55. The increase reflects a lower weighted average diluted share count, which is partly offset by higher net interest expense because cash used for buybacks reduced investment income.
Does Walgreens still hold a significant stake in Cencora?
Yes. After the repurchase, Walgreens owns 24,418,171 shares, about 12% of the 196,928,527 shares outstanding. Investors should watch for further sales, since a large remaining position could affect the share price if sold into the market.
What is the financial impact on Cencora's cash position?
The approximately $400 million repurchase reduced cash and investment balances, which increased net interest expense. The filing does not disclose the post-transaction cash balance or leverage, so investors should check the company's periodic reports for these details.
04—Continue